GSK’s new drug, Blenrep, significantly reduces the risk of death or disease progression for multiple myeloma patients compared to standard treatments, according to a recent study. In a trial with 302 patients, 71% of those treated with Blenrep, dexamethasone, and pomalidomide survived without their cancer worsening for a year. This is compared to just 51% of those treated with the standard regimen, including pomalidomide, dexamethasone, and bortezomib.
GSK highlighted Blenrep’s convenience, as it can be administered without hospitalization and is not limited by manufacturing issues like some cell therapies. The positive results were shared at the American Society of Clinical Oncology meeting in Chicago.
Despite setbacks, including its withdrawal from the U.S. market in 2022, Blenrep’s recent trial success indicates a potential resurgence. Over half of the patients on Blenrep were disease-free for a median of 21.8 months, compared to 12.7 months for those on standard treatments. GSK plans to seek global regulatory approval for Blenrep in late 2024.
While some patients experienced reversible eye-related side effects, the benefits of Blenrep show promise for treating multiple myeloma, a common blood cancer affecting many worldwide. This year, the American Cancer Society estimates 35,780 new cases and 12,540 deaths from multiple myeloma in the U.S. alone.
Disclaimer: The views and investment tips expressed by investment experts on Sharepriceindia.com are their own and not those of the website or its management. Sharepriceindia.com advises users to check with certified experts before taking any investment decisions.
